Agios Pharmaceuticals Inc’s filing revealed that its Director FOUSE JACQUALYN A unloaded Company’s shares for reported $0.21 million on Apr 10 ’24. In the deal valued at $27.55 per share,7,791 shares were sold. As a result of this transaction, FOUSE JACQUALYN A now holds 137,396 shares worth roughly $4.56 million.
Then, Foster-Cheek Kaye I sold 1,285 shares, generating $40,632 in total proceeds. Upon selling the shares at $31.62, the Director now owns 5,524 shares.
Before that, Foster-Cheek Kaye I sold 4,415 shares. Agios Pharmaceuticals Inc shares valued at $141,236 were divested by the Director at a price of $31.99 per share. As a result of the transaction, Foster-Cheek Kaye I now holds 6,809 shares, worth roughly $0.23 million.
Cantor Fitzgerald initiated its Agios Pharmaceuticals Inc [AGIO] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early February with a ‘”an Overweight”‘ rating. Goldman also remained covering AGIO and has increased its forecast on November 17, 2022 with a “Neutral” recommendation from previously “Sell” rating. SVB Leerink revised its rating on July 27, 2022. It rated AGIO as “an Outperform” which previously was an “a Mkt perform”.
Price Performance Review of AGIO
On Monday, Agios Pharmaceuticals Inc [NASDAQ:AGIO] saw its stock fall -3.82% to $33.22. Over the last five days, the stock has gained 1.40%. Agios Pharmaceuticals Inc shares have risen nearly 49.17% since the year began. Nevertheless, the stocks have risen 34.93% over the past one year. While a 52-week high of $35.50 was reached on 02/27/24, a 52-week low of $19.80 was recorded on 01/19/24. SMA at 50 days reached $30.69, while 200 days put it at $25.76. A total of 0.68 million shares were traded, compared to the trading of 0.69 million shares in the previous session.
Levels Of Support And Resistance For AGIO Stock
The 24-hour chart illustrates a support level at 32.58, which if violated will result in even more drops to 31.95. On the upside, there is a resistance level at 34.48. A further resistance level may holdings at 35.75. The Relative Strength Index (RSI) on the 14-day chart is 62.69, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.25, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 33.38%. Stochastics %K at 80.33% indicates the stock is a selling.
The most recent change occurred on December 03, 2021 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $54 price target.
